Comments on: Pharvaris Drug for Rare Swelling Disease Meets Phase 3 Goals; FDA Filing Planned for 2026

Comments on: Pharvaris Drug for Rare Swelling Disease Meets Phase 3 Goals; FDA Filing Planned for 2026 https://medcitynews.com/2025/12/pharvaris-hae-deucrictibant-rare-disease-hereditary-angioedema-bradykinin-b2-antagonist/ Healthcare technology news, life science current events Wed, 03 Dec 2025 23:47:01 +0000 hourly 1 https://wordpress.org/?v=6.8.5